retatrutide case study just delivered the first top-line Phase 3 results for a triple agonist in obesity — and the findings from TRIUMPH-4 are striking👇 Retatrutide Significantly Reduces Visceral Fat

Additional costs The medication price is not the only expense

Clinical Trial Pipeline: 170+ Peptides in Active Development More than 170 peptides are in active clinical development, with over 280 peptide drugs undergoing preclinical and clinical studies

Genetic engineering creates new opportunities In the early 1970s a new tool appeared on the scene called recombinant DNA technology or genetic engineering

Kusunoki M, Sato D, Nakamura T, Oshida Y, Tsutsui H, Natsume Y, Tsutsumi K, Miyata T

Societies and others weigh in Several medical societies and health care professionals have addressed concerns about safety of off-brand GLP-1s

This evidence challenges the conventional approach of delaying medication intervention and offers practitioners new options for tailoring obesity treatment to individual response patterns